Icure Pharmaceutical Incorporation (KOSDAQ:175250)
1,920.00
-57.00 (-2.88%)
At close: May 12, 2025, 3:30 PM KST
KOSDAQ:175250 Revenue
In the year 2024, Icure Pharmaceutical Incorporation had annual revenue of 69.21B KRW with 21.83% growth. Icure Pharmaceutical Incorporation had revenue of 20.70B in the quarter ending December 31, 2024, with 71.02% growth.
Revenue
69.21B
Revenue Growth
+21.83%
P/S Ratio
1.04
Revenue / Employee
317.46M
Employees
218
Market Cap
71.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.21B | 12.40B | 21.83% |
Dec 31, 2023 | 56.81B | -2.56B | -4.31% |
Dec 31, 2022 | 59.37B | -4.92B | -7.65% |
Dec 31, 2021 | 64.28B | -25.86B | -28.69% |
Dec 31, 2020 | 90.14B | 29.22B | 47.97% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Electronics | 308.07T |
SK hynix | 71.40T |
LG Energy Solution | 25.76T |
Samsung Biologics | 4,547.32B |
Hyundai Motor Company | 178.98T |
Hanwha Aerospace | 11.24T |
HD Hyundai Heavy Industries | 14.49T |
Kia Corporation | 107.45T |